Search is Powered by Google
Cancer / Oncology News

Enzyme That Sensitizes Cells To Chemotherapeutics Could Also Be New Anti-cancer Target

Main Category: Cancer / Oncology
Also Included In: Lung Cancer
Article Date: 20 Aug 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Researchers at Van Andel Institute (VAI) and Novartis Institutes for Biomedical Research have identified an important enzyme required for cancer cell survival. Lowering levels of the enzyme caused a wide variety of cancer cells to die, reduced proliferation of cancer cells, and sensitized cancer cells to commonly used chemotherapeutic agents, such as the drug Taxol. The cells in the study included pancreatic, prostate, and lung cancer cells.

"We have identified a previously unrecognized anti-cancer target," said VAI Scientific Investigator Jeff MacKeigan, Ph.D. "For some reason, cancer cells become 'addicted' to certain genes. When we blocked the gene that results in the enzyme PI3K-C2alpha using a fairly new tool used extensively by our lab called RNA interference, we found this had an abrupt adverse effect on a variety of cancer cells."

The findings, published in Molecular Cancer Research, examined the role of an often overlooked class of phosphoinositide 3-kinase enzymes and found that one of the enzymes, called PI3K-C2alpha, was required for several types of cancer cells to survive. Researchers found that lowering levels of this enzyme reduced proliferation in a number of cancer cell lines, and they were able to determine a critical threshold level of PI3K-C2alpha below which cell death was "switched on."

"Although we must further determine what happens in normal cells to confirm the therapeutic value, we also found that decreasing levels of PI3K-Class 2 alpha to a certain point didn't kill the cancer cells, but did sensitize them to chemotherapeutic agents such as Taxol," said MacKeigan. "This alone could contribute to a more effective anti-cancer strategy in a subset of cancers."

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process.

Van Andel Institute

View drug information on Taxol.





Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...